66 related articles for article (PubMed ID: 19578749)
1. Matriptase and its putative role in cancer.
Uhland K
Cell Mol Life Sci; 2006 Dec; 63(24):2968-78. PubMed ID: 17131055
[TBL] [Abstract][Full Text] [Related]
2. Measurement of protein kinase B activity in single primary human pancreatic cancer cells.
Proctor A; Herrera-Loeza SG; Wang Q; Lawrence DS; Yeh JJ; Allbritton NL
Anal Chem; 2014 May; 86(9):4573-80. PubMed ID: 24716819
[TBL] [Abstract][Full Text] [Related]
3. Building up the tension between the epithelial and stromal compartment in pancreatic ductal adenocarcinoma.
Biffi G; Öhlund D; Tuveson D
Cell Death Differ; 2016 Aug; 23(8):1265-6. PubMed ID: 27285108
[No Abstract] [Full Text] [Related]
4. Author Correction: Genotype tunes pancreatic ductal adenocarcinoma tissue tension to induce matricellular fibrosis and tumor progression.
Laklai H; Miroshnikova YA; Pickup MW; Collisson EA; Kim GE; Barrett AS; Hill RC; Lakins JN; Schlaepfer DD; Mouw JK; LeBleu VS; Roy N; Novitskiy SV; Johansen JS; Poli V; Kalluri R; Iacobuzio-Donahue CA; Wood LD; Hebrok M; Hansen K; Moses HL; Weaver VM
Nat Med; 2024 Mar; 30(3):908. PubMed ID: 38017076
[No Abstract] [Full Text] [Related]
5. Retraction Note: Vacuolar protein sorting 35 (VPS35) acts as a tumor promoter via facilitating cell cycle progression in pancreatic ductal adenocarcinoma.
Gai Y; Qian L; Jiang S; Li J; Zhang X; Yang X; Pan H; Liao Y; Wang H; Huang S; Zhang S; Nie H; Ma M; Li H
Funct Integr Genomics; 2024 May; 24(3):101. PubMed ID: 38750380
[No Abstract] [Full Text] [Related]
6. Retraction Note: MicroRNA-454 regulates stromal cell derived factor-1 in the control of the growth of pancreatic ductal adenocarcinoma.
Fan Y; Xu LL; Shi CY; Wei W; Wang DS; Cai DF
Sci Rep; 2023 Dec; 13(1):21495. PubMed ID: 38057430
[No Abstract] [Full Text] [Related]
7. Commentary: Special Issue - Current Understanding of Colorectal and Pancreatic Cancers.
Vodicka P; Vodickova L
Mutagenesis; 2024 Mar; ():. PubMed ID: 38551731
[TBL] [Abstract][Full Text] [Related]
8. Author Correction: Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma.
Mazur PK; Herner A; Mello SS; Wirth M; Hausmann S; Sánchez-Rivera FJ; Lofgren SM; Kuschma T; Hahn SA; Vangala D; Trajkovic-Arsic M; Gupta A; Heid I; Noël PB; Braren R; Erkan M; Kleeff J; Sipos B; Sayles LC; Heikenwalder M; Heßmann E; Ellenrieder V; Esposito I; Jacks T; Bradner JE; Khatri P; Sweet-Cordero EA; Attardi LD; Schmid RM; Schneider G; Sage J; Siveke JT
Nat Med; 2024 May; ():. PubMed ID: 38816611
[No Abstract] [Full Text] [Related]
9. How I treat pancreatic ductal adenocarcinoma.
Tempero MA
J Oncol Pract; 2008 Jan; 4(1):46-7. PubMed ID: 20859443
[No Abstract] [Full Text] [Related]
10. Time-domain in vivo near infrared fluorescence imaging for evaluation of matriptase as a potential target for the development of novel, inhibitor-based tumor therapies.
Napp J; Dullin C; Müller F; Uhland K; Petri JB; van de Locht A; Steinmetzer T; Alves F
Int J Cancer; 2010 Oct; 127(8):1958-74. PubMed ID: 20473895
[TBL] [Abstract][Full Text] [Related]
11. The Effects of Matriptase Inhibition on the Inflammatory and Redox Homeostasis of Chicken Hepatic Cell Culture Models.
Barna RF; Mackei M; Pászti-Gere E; Neogrády Z; Jerzsele Á; Mátis G
Biomedicines; 2021 Apr; 9(5):. PubMed ID: 33919461
[TBL] [Abstract][Full Text] [Related]
12. Exposure of human intestinal epithelial cells and primary human hepatocytes to trypsin-like serine protease inhibitors with potential antiviral effect.
Pászti-Gere E; Pomothy J; Jerzsele Á; Pilgram O; Steinmetzer T
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):659-668. PubMed ID: 33641565
[TBL] [Abstract][Full Text] [Related]
13. Cell surface-anchored serine proteases in cancer progression and metastasis.
Martin CE; List K
Cancer Metastasis Rev; 2019 Sep; 38(3):357-387. PubMed ID: 31529338
[TBL] [Abstract][Full Text] [Related]
14. 6-Substituted Hexamethylene Amiloride (HMA) Derivatives as Potent and Selective Inhibitors of the Human Urokinase Plasminogen Activator for Use in Cancer.
Buckley BJ; Aboelela A; Minaei E; Jiang LX; Xu Z; Ali U; Fildes K; Cheung CY; Cook SM; Johnson DC; Bachovchin DA; Cook GM; Apte M; Huang M; Ranson M; Kelso MJ
J Med Chem; 2018 Sep; 61(18):8299-8320. PubMed ID: 30130401
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of hepatocyte growth factor activator inhibitor type 1 (HAI-1) immunoreactivity in pancreatic ductal adenocarcinoma.
Sakugawa C; Haruyama Y; Tanaka H; Fukushima T; Kawaguchi M; Kataoka H
BMC Res Notes; 2017 Dec; 10(1):674. PubMed ID: 29202869
[TBL] [Abstract][Full Text] [Related]
16. Type II transmembrane serine proteases as potential targets for cancer therapy.
Murray AS; Varela FA; List K
Biol Chem; 2016 Sep; 397(9):815-26. PubMed ID: 27078673
[TBL] [Abstract][Full Text] [Related]
17. Combinatorial optimization of cystine-knot peptides towards high-affinity inhibitors of human matriptase-1.
Glotzbach B; Reinwarth M; Weber N; Fabritz S; Tomaszowski M; Fittler H; Christmann A; Avrutina O; Kolmar H
PLoS One; 2013; 8(10):e76956. PubMed ID: 24146945
[TBL] [Abstract][Full Text] [Related]
18. Use of IHC and newly designed matriptase inhibitors to elucidate the role of matriptase in pancreatic ductal adenocarcinoma.
Uhland K; Siphos B; Arkona C; Schuster M; Petri B; Steinmetzer P; Mueller F; Schweinitz A; Steinmetzer T; Van De Locht A
Int J Oncol; 2009 Aug; 35(2):347-57. PubMed ID: 19578749
[TBL] [Abstract][Full Text] [Related]
19. In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma.
Förbs D; Thiel S; Stella MC; Stürzebecher A; Schweinitz A; Steinmetzer T; Stürzebecher J; Uhland K
Int J Oncol; 2005 Oct; 27(4):1061-70. PubMed ID: 16142324
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
